Dihexa

Dihexa (PNB-0408) is a hexapeptide-derived small peptidomimetic developed by Joseph Harding and John Wright at Washington State University. It was designed by structural modification of angiotensin IV (Ang IV), an endogenous brain peptide with procognitive effects but poor metabolic stability and CNS penetration. The chemical structure is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, sometimes written Hexanoyl-Tyr-Ile-Ahx-NH₂. The compound has been investigated as a potential treatment for cognitive decline in Alzheimer's disease and related dementias. As of May 2026, evidence is restricted to in vitro and rodent studies. No human clinical trial has been published.

From Angiotensin IV to Dihexa

The Harding-Wright research program began in the 1990s investigating the cognitive effects of angiotensin IV (Ang IV), a six-amino-acid fragment of angiotensin II. Early work by the Pederson, Krishnan, Harding, and Wright group, published in Regulatory Peptides in 2001, showed that an Ang IV analog (Nle1-angiotensin IV) reversed scopolamine-induced spatial memory deficits in rats. The effect was initially attributed to a distinct "AT4 receptor" in the hippocampus.

Native Ang IV is enzymatically degraded within minutes and does not cross the blood-brain barrier well. The Harding group set out to design analogs that would be stable and brain-penetrant. Sequential structure-activity-relationship work identified small modifications (N-terminal hexanoylation, C-terminal aminohexanoic amide) that produced Dihexa: orally bioavailable, BBB-penetrant, metabolically stable, and at least as procognitive in rodent models as native Ang IV.

In 2014, Benoist and colleagues reported that the procognitive and synaptogenic effects of angiotensin IV-derived peptides were dependent on hepatocyte growth factor (HGF) / c-Met receptor activation, not on the AT4 receptor as had been assumed for two decades. This was a substantial mechanistic reassignment for the entire angiotensin IV cognitive pharmacology field.

The Retraction

One of the foundational papers in the AT4-to-c-Met reassignment from the Harding-Wright program was retracted following the publication of Benoist 2014 over data-integrity concerns. The retraction is important context for any reader evaluating Dihexa's evidence base. It does not invalidate every downstream finding (independent laboratories have at least partially replicated cognitive-rescue effects of Dihexa in rodents), but it means the upstream mechanism story has at least one bad citation in its history.

Honest evidence framing: the cognitive-rescue effect in rodent models has some independent replication. The specific molecular-pharmacology claim that Dihexa works through HGF/c-Met is supported by some independent biochemistry but originated in a program with a documented data-integrity event.

Key Rodent Studies

• 2013, McCoy et al., J Pharmacol Exp Ther: showed that Dihexa and related metabolically stabilized Ang IV analogs reverse scopolamine-induced and aging-related memory deficits in rats, with Dihexa active at lower doses than earlier analogs.
• 2014, Benoist et al., J Pharmacol Exp Ther: established the HGF/c-Met dependency of the cognitive effects.
• 2021, Chen et al., APP/PS1 mouse model: showed that Dihexa restored spatial learning and memory (Morris water maze) in transgenic APP/PS1 mice (a standard Alzheimer's model), increased synaptophysin (SYP) expression, reduced astrocyte and microglia activation, decreased IL-1β and TNF-α, and increased IL-10. Mechanism was linked to PI3K/AKT signaling downstream of c-Met.

The synaptogenesis potency claim ("10 million times more potent than BDNF") refers to the in vitro cell-culture assay reported in the original Harding-Wright Science publication. In dissociated hippocampal neuron culture, Dihexa induced new synaptic puncta at picomolar concentrations, while BDNF required nanomolar concentrations for equivalent synaptogenic activity. The seven-orders-of-magnitude difference is real in that specific in vitro context and frequently misused as a general statement of in vivo potency or clinical effect.

Regulatory Status

Dihexa has no regulatory approval anywhere. It is not in any active FDA Investigational New Drug program as of public records. It is sold as a research chemical by laboratory-supply companies and as oral capsules, topical creams, and intranasal spray solutions by research-peptide vendors targeting biohacking communities. None of these are FDA-approved or pharmaceutical-grade.

A related angiotensin-IV-pathway pharmaceutical compound from a different program has reportedly failed in late-stage clinical trials for cognitive indications, though Dihexa itself has not been tested in humans in any registered trial.

The proposed mechanism centers on hepatocyte growth factor (HGF) and its receptor, c-Met. HGF is a pleiotropic growth factor produced primarily in mesenchymal cells, acting on epithelial and neural cells expressing c-Met. In the CNS, HGF/c-Met signaling supports neuronal survival, axonal outgrowth, synaptogenesis, and dendritic arborization. The system is active in development and persists at lower levels into adulthood, where it appears to support synaptic plasticity.

Dihexa is described as a potentiator rather than a simple agonist. The current model is that Dihexa binds HGF with high affinity, increasing HGF-c-Met dimerization and signaling output without itself directly activating c-Met. The compound has reportedly low intrinsic activity at c-Met in the absence of HGF.

Downstream signaling consequences in neurons:

• PI3K/AKT activation, the canonical c-Met effector pathway, supporting cell survival
• MAPK/ERK activation, supporting plasticity-related gene expression
• mTOR activation downstream of PI3K/AKT, supporting protein synthesis required for memory consolidation
• Increased synaptic density as measured by SYP and PSD-95 expression in rodent brain tissue
• Increased dendritic spine density in hippocampal neurons

The compound is orally bioavailable in rodents and crosses the blood-brain barrier, properties that distinguish it from native Ang IV and from BDNF itself. Both of those advantages were the explicit design targets of the Harding-Wright program.

The c-Met dependency means Dihexa is most active in tissues where the receptor is expressed: brain, kidney, liver, certain immune cell populations. CNS effects are the most studied. Peripheral effects of chronic systemic Dihexa exposure are not well characterized.

Rodent cognitive data:

• Rescue of scopolamine-induced spatial memory deficits in adult rats (McCoy 2013)
• Rescue of age-related cognitive decline in aged rats (Harding lab work)
• Improved Morris water maze performance in APP/PS1 transgenic mice (Chen 2021)
• Increased synaptophysin (SYP) expression in mouse hippocampus
• Reduced astrocyte and microglia activation in Alzheimer's mouse model
• Decreased pro-inflammatory cytokines (IL-1β, TNF-α) and increased anti-inflammatory IL-10
• Increased dendritic arborization in cell culture

In vitro data:

• Synaptogenesis in dissociated hippocampal neuron culture at picomolar concentrations
• PI3K/AKT pathway activation in neuronal cell lines
• Dose-response curve consistent with high-affinity HGF binding

Human data: zero published controlled studies.

Anecdotal reports from biohacking and nootropic communities describe subjective enhancement of learning, memory consolidation, focus, and "neuroplasticity" perceived as improved associative thinking. Reports also describe headaches, mood changes, and unusual subjective effects on perception in some users. These are uncontrolled, often single-user reports, frequently from people using multiple compounds simultaneously.

The "permanently rewires the brain" framing common in marketing is not supported by any clinical evidence and overstates what synaptogenesis even means physiologically. Synapses are dynamic structures that form and dissolve constantly; an intervention that increases the rate of new synapse formation does not lock those synapses in place.

Rodent dosing in published studies: typically 0.5 to 2 mg/kg oral or intraperitoneal, daily or every other day, for 1 to 4 weeks. The Chen 2021 APP/PS1 study used doses of 0.005 mg/kg, 0.05 mg/kg, and 0.5 mg/kg by intraperitoneal injection in mice over 12 weeks.

For a 70 kg human, naïve allometric scaling from a 25 g mouse at 0.5 mg/kg gives a human-equivalent dose of approximately 40 mcg per day. This is far below community oral protocols. The scaling is unreliable for peptidomimetics with unknown human bioavailability, so this number is illustrative only.

Off-label community protocols in biohacking and nootropic spaces vary widely:

• Oral: 8 to 45 mg per day, typically once daily in the morning, often cycled 4 to 12 weeks on, several weeks off
• Sublingual or buccal: 5 to 25 mg
• Topical: 8 to 25 mg applied to the temples or behind the ear with DMSO as a penetration enhancer (the rationale here is to maximize CNS delivery while minimizing systemic exposure)
• Intranasal: rare, doses inconsistent

None of these protocols are validated against human pharmacokinetic data, because none exists. The wide variation in doses circulating is symptomatic of a research-chemical market filling a void where no clinical pharmacokinetic study has been conducted.

The half-life and duration of action in humans are not characterized. Community reports describe effects persisting beyond 48 hours after dosing, which would be consistent with the proposed mechanism (synaptic structural changes outlast the chemical exposure) but does not confirm anything about plasma kinetics.

No standardized human dosing protocol exists for Dihexa.

Rodent safety data: short-duration studies (a few weeks at standard rodent doses) did not show overt toxicity. Body weight, behavior, and gross organ pathology were not affected. The Chen 2021 APP/PS1 study did not report adverse-event burden at the doses used.

Human safety data: none.

Specific theoretical concerns that have not been resolved:

• Cancer risk: c-Met signaling is implicated in oncogenesis in multiple solid tumor types (gastric, lung, hepatocellular, renal cell carcinomas frequently overexpress c-Met or carry activating mutations). HGF-potentiating activity in someone with occult or active malignancy is a serious unresolved concern. Dihexa should not be used by anyone with current or recent cancer history, regardless of remission status, without medical monitoring.
• Fibrosis: HGF/c-Met activation is associated with pulmonary, hepatic, and renal fibrosis under some conditions, though paradoxically HGF can also be anti-fibrotic in others. The dose- and context-dependence has not been characterized for chronic exposure.
• Pregnancy and fertility: HGF is critical for placental development. Dihexa should not be used in pregnancy or in those planning pregnancy.
• Cerebrovascular effects: angiotensin-IV-pathway compounds can have effects on cerebral blood flow that are not fully characterized in chronic exposure.
• Drug interactions: not characterized. CYP450 metabolism profile of Dihexa has not been published. Interactions with common medications are theoretical only.
• Vendor purity: the absence of pharmaceutical-grade manufacturing means that products marketed as Dihexa vary in actual content, purity, and stability. Third-party analytical testing of research-chemical Dihexa products has shown inconsistent results across vendors.

Reported user effects that have been mentioned in nootropic communities include headaches (sometimes severe), insomnia, irritability, mood lability, and visual disturbances. None of these have been characterized in any controlled study.

Dihexa is in a different mechanistic class from most peptide-based nootropics. The closest comparators:

• Cerebrolysin: a porcine-brain-derived peptide preparation with BDNF-like effects, available pharmaceutically in some European and Asian markets. Cerebrolysin has more human clinical data than Dihexa, including controlled trials in dementia and stroke recovery. Mechanism is broader and less specific than Dihexa's proposed HGF/c-Met targeting.
• Semax and Selank: Russian-developed nootropic peptides with cholinergic and serotonergic effects respectively. Substantially more human-use history than Dihexa (decades in Russia) and meaningfully safer in that empirical sense. Mechanistically unrelated.
• BDNF: the canonical neurotrophic factor. Cannot be administered systemically because of poor bioavailability and BBB penetration. Various BDNF-pathway modulators have been investigated for cognitive indications with mixed results.
• HGF directly: full-length HGF protein has been investigated for cardiovascular and neurological indications. Stability and delivery problems have limited clinical translation.

Common biohacker stacks circulating in nootropic communities pair Dihexa with:

• Semax or Selank for combined HGF/c-Met (Dihexa) and cholinergic/serotonergic (Semax/Selank) modulation
• Lion's Mane mushroom for combined neurotrophic signaling
• Modafinil or other dopaminergic stimulants for acute alertness on top of Dihexa's proposed structural effects

None of these combinations have been studied in controlled trials. The cardiovascular and CNS burden of combining Dihexa with stimulants is not characterized.

Combinations to avoid:

• Any current cancer treatment or active malignancy: the HGF/c-Met angle makes Dihexa potentially counterproductive in oncology
• Pregnancy or planned pregnancy: HGF role in placental development makes exposure during conception or gestation unwise
• MAO inhibitors or SSRIs/SNRIs: while no specific interaction is established, the unstudied interaction profile combined with reports of subjective mood effects makes combination unwise without medical oversight

The most actionable framing of Dihexa in 2026: the compound has the most aggressive structural-pharmacology rationale of any nootropic peptide circulating in research-chemical markets, the data base supporting that rationale is mixed (some independent replication, one upstream retraction), and there is zero human safety data. Users at the more cautious end of the biohacker spectrum often choose to wait until a controlled human trial is published before considering Dihexa specifically, given the alternatives like Semax, Selank, and Cerebrolysin that have meaningfully more human-use history.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.